title: Early changes in plasma glucagon and growth hormone response to oral glucose in experimental hyperthyroidism.
abstract: The mechanisms underlying deterioration of glucose tolerance associated with hyperthyroidism are not completely understood. Increases in glucagon and growth hormone (GH) secretion have been previously found in hyperthyroid subjects, and could play a crucial role in this phenomenon. However, studies have not yet established the time sequence of changes in plasma glucose on the one hand and glucagon and GH on the other. To assess the early effects of thyroid hormone excess on glucose tolerance and plasma concentrations of the main glucoregulatory hormones, 12 nondiabetic euthyroid subjects underwent an oral glucose tolerance test (OGTT) before and after triiodothyronine ([T3] 120 micrograms/d) was administered for 10 days. Plasma levels of glucose, insulin, glucagon, and GH were determined at fasting and after the glucose load. T3 administration caused a marked increase in serum T3 (8.8 +/- 0.6 v 2.0 +/- 0.1 nmol/L), with clinical and biochemical signs of thyrotoxicosis. During the treatment, plasma glucose significantly increased both at fasting and after the glucose load (basal, 5.3 +/- 0.1 v 4.9 +/- 0.2 mmol/L, P < .05; area under the curve [AUC] for OGTT, 7.7 +/- 0.3 v 6.7 +/- 0.4 mmol/L min, P < .01) without any change in plasma insulin levels. After T3 administration, plasma glucagon levels were lower than at baseline (basal, 92 +/- 7 v 148 +/- 35 ng/L; AUC, 74 +/- 6 v 98 +/- 16 ng/L.min, P < .05), showing an appropriate reduction by the increased glucose levels. Conversely, plasma GH showed impaired suppression by hyperglycemia (AUC, 1.2 +/- 0.3 v 0.7 +/- 0.2 microgram/L.min, P < .05). In conclusion, thyroid hormone excess rapidly impairs glucose tolerance. Altered secretion of GH is an early event in thyrotoxicosis accompanying the onset of hyperglycemia, whereas plasma glucagon is appropriately suppressed by the increased plasma glucose levels. Thus, GH but not glucagon may contribute to the early hyperglycemic effect of thyrotoxicosis.
authors.affiliation: Division of Endocrinology and Metabolic Diseases, University of Verona, Ospedale Maggiore, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Tosi
authors.forename: P
authors.initials: P
authors.lastname: Moghetti
authors.forename: R
authors.initials: R
authors.lastname: Castello
authors.forename: C
authors.initials: C
authors.lastname: Negri
authors.forename: E
authors.initials: E
authors.lastname: Bonora
authors.forename: M
authors.initials: M
authors.lastname: Muggeo
mesh_terms: D000284:Administration, Oral; D000328:Adult; D005260:Female; D005934:Glucagon / Q000097:blood*; D005947:Glucose / Q000378:metabolism / Q000494:pharmacology*; D005951:Glucose Tolerance Test; D013006:Growth Hormone / Q000097:blood*; D006728:Hormones / Q000097:blood; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood* / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D014284:Triiodothyronine
chemical_list: D006728:Hormones; D014284:Triiodothyronine; D013006:Growth Hormone; D005934:Glucagon; D005947:Glucose